How This Evidence Evolved
SGLT2 Inhibitors in Heart Failure
From glucose-lowering agent to pillar of heart failure therapy
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
HR 0.67 (95% CI 0.52–0.85), p<0.001 for CV death, HF hospitalisation, urgent HF visit
HR 0.79 (95% CI 0.69–0.90), p<0.001 for CV death or HF hospitalisation
HR 0.82 (95% CI 0.73–0.92), p<0.001 for worsening HF or CV death
Integration into clinical practice guidelines and recommendations
HFrEF: dapagliflozin/empagliflozin, I A
HFmrEF/HFpEF: SGLT2i Class I, Level A
Class I: symptomatic chronic HFrEF; IIa: HFpEF
Current standard of care and ongoing research directions
Landmark Trials in This Story
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
3-point MACE: HR 0.86 (95.02% CI 0.74–0.99), P=0.04
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
HR 0.74 (95% CI 0.65–0.85), p<0.001 for worsening HF or CV death
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
HR 0.75 (95% CI 0.65–0.86), p<0.001 for CV death or HF hospitalisation
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
HR 0.67 (95% CI 0.52–0.85), p<0.001 for CV death, HF hospitalisation, urgent HF visit
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
HR 0.79 (95% CI 0.69–0.90), p<0.001 for CV death or HF hospitalisation
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
HR 0.82 (95% CI 0.73–0.92), p<0.001 for worsening HF or CV death
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.